W. K. Patterson

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Jayesh Desai, Hui Gan, Catherine Barrow et al. · Journal of Clinical Oncology · 2020 · 109 citations · Full text

Medicine, Oncology, Pharmacology +13

Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study

Ken Pittman, Ian Olver, Bogda Koczwara et al. · British Journal of Cancer · 2006 · 38 citations · Full text

Medicine, Oncology, Pharmacology +11

Rifampicin as treatment for pruritus in malignant cholestasis

Timothy Price, W. K. Patterson, Ian Olver · Supportive Care in Cancer · 1998 · 23 citations

Pharmacy, Pharmacology, Pharmacotherapy +6

A phase I study to determine the safety, tolerability and maximum tolerated dose of green-lipped mussel (Perna canaliculus) lipid extract, in patients with advanced prostate and breast cancer

Shawgi Sukumaran, Ken Pittman, W. K. Patterson et al. · Annals of Oncology · 2009 · 13 citations

Pharmacy, Pharmacokinetics, Pharmacology +5